全文获取类型
收费全文 | 5866篇 |
免费 | 316篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 101篇 |
妇产科学 | 102篇 |
基础医学 | 766篇 |
口腔科学 | 83篇 |
临床医学 | 521篇 |
内科学 | 1524篇 |
皮肤病学 | 80篇 |
神经病学 | 600篇 |
特种医学 | 166篇 |
外科学 | 778篇 |
综合类 | 20篇 |
预防医学 | 371篇 |
眼科学 | 152篇 |
药学 | 466篇 |
中国医学 | 9篇 |
肿瘤学 | 460篇 |
出版年
2023年 | 22篇 |
2022年 | 64篇 |
2021年 | 185篇 |
2020年 | 100篇 |
2019年 | 142篇 |
2018年 | 170篇 |
2017年 | 103篇 |
2016年 | 138篇 |
2015年 | 150篇 |
2014年 | 241篇 |
2013年 | 308篇 |
2012年 | 456篇 |
2011年 | 509篇 |
2010年 | 264篇 |
2009年 | 235篇 |
2008年 | 365篇 |
2007年 | 411篇 |
2006年 | 376篇 |
2005年 | 367篇 |
2004年 | 330篇 |
2003年 | 311篇 |
2002年 | 261篇 |
2001年 | 57篇 |
2000年 | 42篇 |
1999年 | 52篇 |
1998年 | 66篇 |
1997年 | 53篇 |
1996年 | 38篇 |
1995年 | 36篇 |
1994年 | 35篇 |
1993年 | 16篇 |
1992年 | 28篇 |
1991年 | 20篇 |
1990年 | 22篇 |
1989年 | 18篇 |
1988年 | 15篇 |
1987年 | 15篇 |
1986年 | 13篇 |
1985年 | 22篇 |
1984年 | 15篇 |
1983年 | 25篇 |
1982年 | 13篇 |
1981年 | 10篇 |
1980年 | 13篇 |
1979年 | 9篇 |
1978年 | 13篇 |
1977年 | 9篇 |
1974年 | 8篇 |
1970年 | 4篇 |
1968年 | 4篇 |
排序方式: 共有6224条查询结果,搜索用时 31 毫秒
121.
122.
123.
124.
125.
126.
127.
128.
Diabetes during pregnancy results in congenital malformations and long-term postnatal diseases. Experimental models are still needed to investigate the mechanism responsible for these alterations. Thus, by the administration of different doses of streptozotocin (STZ) (0, 25, 30, or 35 mg/kg body weight, intravenous) at the onset of pregnancy in rats, the present study sought an appropriate animal model for this pathology. At day 6 of pregnancy, plasma glucose was progressively higher with an increasing STZ dose, and in rats receiving the 35-mg dose, 2 subgroups were detected: some animals had plasma glucose levels above controls but below 200 mg/dL (mildly diabetic, MD), whereas others had levels above 400 mg/dL (severely diabetic, SD). At day 20 of pregnancy, the MD rats had normal glycemia, but after an oral glucose load (2 g/kg body weight), plasma glucose increased more and insulin increased less than in controls. The SD rats maintained their hyperglycemia and had a greatly impaired oral glucose tolerance. At day 20, fetuses of SD dams were fewer, weighed less, and had enhanced plasma glucose and triglycerides and decreased insulin, whereas those from MD dams did not differ from controls. At birth, newborns from MD dams had higher body weight, plasma insulin, and liver triglycerides as well as total body lipid concentrations than controls, and on day 21, remained macrosomic and showed higher plasma glucose and liver triglyceride concentrations. At 70 days of age, offspring of MD dams had impaired oral glucose tolerance but normal plasma insulin change in the case of females, whereas plasma insulin increased less in males. These alterations were manifest more in those offspring from dams that had >50% macrosomic newborns than in those from dams that had <50% macrosomic newborns. In conclusion, whereas our MD rats mimic the changes taking place in gestational diabetic women and show the long-term risk of macrosomia, the SD rats are more similar to uncontrolled diabetics. Thus these two rat models, obtained with moderate amounts of STZ, could be used to study the pathophysiological consequences of these different diabetic conditions. 相似文献
129.
Victor Alfonso Jimenez Diaz Antonio Tello-Montoliu Raul Moreno Ignacio Cruz Gonzalez Jose Antonio Baz Alonso Rafael Romaguera Eduardo Molina Navarro Pablo Juan Salvadores Emilio Paredes Galan Antonio De Miguel Castro Guillermo Bastos Fernandez Alberto Ortiz Saez Saleta Fernandez Barbeira Sergio Raposeiras Roubin Juan Ocampo Miguez Antonio Serra Peñaranda Mariano Valdes Chavarri Angel Cequier Fillat Andres Iñiguez Romo 《JACC: Cardiovascular Interventions》2019,12(1):22-32
Objectives
The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI.Background
Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence.Methods
This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU <208) in ≥70% of patients treated with ticagrelor at 90 days post-TAVR.Results
A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273 ± 09) and were randomized to aspirin + ticagrelor (n = 24, PRU 277 ± 08) or continued with aspirin + clopidogrel (n = 24, PRU 269 ± 49). The remaining 20 patients (29%) without HPR (PRU 133 ± 12) were included in the registry. Overall, platelet reactivity across all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at baseline developed HPR status during the first month after TAVR.Conclusions
HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR. Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066) 相似文献130.